CG Oncology Inc (Ticker: CGON US) is a biotechnology company based in the United States, focused on developing and commercializing innovative immunotherapies for urologic cancer patients, with a particular emphasis on bladder cancer. Their leading product candidate is cretostimogene grenadenorepvec, an investigational engineered oncolytic immunotherapy designed as a potential bladder-sparing therapeutic for patients with bladder cancer. However, it's important to note that cretostimogene grenadenorepvec is currently not approved by any regulatory agency, and its safety and effectiveness have not been established.

CG Oncology Inc plans to go public through an Initial Public Offering on NASDAQ GM. The IPO is set to launch on January 25, 2024. The company expects to raise USD 306 million, offering 17 million shares at an expected price range of USD 16.00 to 18.00 per share. Additionally, there is a greenshoe option of 15%, amounting to 2.55 million shares. The offering is managed by Morgan Stanley & Co Inc (Left Lead), Cantor Fitzgerald & Co, and Goldman Sachs.